Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study.
about
Opioid-induced constipation: advances and clinical guidanceA critical appraisal of lubiprostone in the treatment of chronic constipation in the elderlyConsensus Recommendations on Initiating Prescription Therapies for Opioid-Induced ConstipationEmerging therapies for patients with symptoms of opioid-induced bowel dysfunctionChronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunitiesImaging opioid analgesia in the human brain and its potential relevance for understanding opioid use in chronic pain.Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart reviewPersistent constipation and abdominal adverse events with newer treatments for constipation.Overview and treatment of opioid-induced constipation.Advances in pharmacotherapy for opioid-induced constipation - a systematic review.A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension.Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate responseAnalysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer painEfficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis.Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomesOpioid-Induced Constipation among a Convenience Sample of Patients with Cancer Pain.Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced ConstipationUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy.Methylnaltrexone for the treatment of opioid-induced constipation.Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis.Use of methylnaltrexone to induce laxation in acutely injured patients with burns and necrotizing soft-tissue infections.Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone.Narcotic bowel syndrome and opioid-induced constipation.Management of opioid-induced constipation for people in palliative care.New Options in Constipation Management.Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs.Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.Opioid-Related Constipation in Patients With Non-cancer Pain Syndromes: a Review of Evidence-Based Therapies and Justification for a Change in Nomenclature.Opioids and GI Motility-Friend or Foe?Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline.Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial.Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation.Opioid-induced bowel dysfunction.Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain.Peripherally Acting µ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis.
P2860
Q26765571-A4786414-5BB0-4CC6-A27B-B54BFC0BE62CQ26824999-385465EE-C38E-42A8-920F-D096C1A2FB00Q26830397-8D14862F-C439-40BF-9DA7-D1D152C2360DQ27010907-4947CF26-F554-427C-A61B-CD88DC786964Q28083547-19E158F7-C11A-455D-ADAF-7FCD32DC3D03Q30657653-251EF294-0985-4BCB-B6E0-7D9312CA9B19Q33461841-4BB7B997-CB4C-4DC1-AF48-9CE3C6820C04Q33468562-DD9E0A2D-F226-4F09-A91D-A9F3A302A6E6Q34352001-54CD80D3-2CA9-489A-8E74-DE418D2B6188Q34455604-C6F11BAE-5873-4D15-AB7F-84924F8F2A54Q35583262-16538702-9EE4-4B2C-8324-8B1D1ADEAC23Q35822213-D1B4E62E-99AA-40D2-9AFE-B4B53FE09611Q36223541-9BE5F2D4-5284-4562-B43C-48CC22D74EAEQ36253231-4310661F-7884-4D08-9627-1219C14619EFQ36384732-1AE15DAD-EB04-4C2A-94E1-970505E03EFAQ36696556-0EF86AD8-9A43-465E-817F-CADBDDC04182Q36978683-C17CA74A-7A7B-480F-A98E-2708872DECC6Q37233788-B003E6FB-C942-4FEB-9648-D623AD498D43Q37362082-B5890C57-05E7-4212-9C3C-927C1765B268Q37491434-5531BB97-51E3-4E37-BF10-78EA75F5657AQ37603682-9D867739-203A-4B2D-8E77-AF91F72BB209Q38069607-1FC6405F-3244-4D62-B77A-61F1EA3E4E6BQ38113454-17703E40-C684-4955-BFC3-6565FB92465BQ38123353-788B9BD0-6838-447F-A5D0-FEFFE8E60821Q38123753-5815BA2B-6B5C-405A-8653-18986DE8A535Q38245693-DD9C921F-6E23-44FB-8A38-F686C9B16A1CQ38540868-E9B631A1-A3A3-446D-8840-73AEFD55D3E4Q38602701-611CC680-13E3-4F3D-99D5-5B3AB9A52A38Q38634906-86503FF2-0145-417B-A202-095EADD80708Q38720981-2E5DF8D1-C746-452C-87E9-F7DBCD90DE36Q38772298-0FD9B642-6F88-4C8E-A512-1C20C3F90D97Q38880480-64A0A2F2-81F3-499C-A583-9C63EF6990EAQ38997203-3382AA23-EFD8-4327-B80D-355CDB8D1D2CQ39051851-EDBF1965-F885-4FF1-8FB4-972E3B2D2518Q39151326-A6B84B7E-1A49-4D8A-A1E0-326BE74C4D64Q39234260-C0FEC544-B116-4F7A-B9A8-90341083139DQ42323281-D4731A17-0024-43D4-90E6-48CE3C84E349Q43075638-68F4DAB0-CD12-4EEF-B33D-37AFC57641F9Q43075966-CA834B71-6BC9-40D1-AC4A-AB0157BEECE4Q44330002-5761A1FC-2E9A-46BF-BE6C-F30ABDFBD9EF
P2860
Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@ast
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@en
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@nl
type
label
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@ast
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@en
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@nl
prefLabel
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@ast
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@en
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@nl
P2093
P1433
P1476
Subcutaneous methylnaltrexone ...... a randomized controlled study.
@en
P2093
Amy Manley
Bruce Randazzo
E Richard Blonsky
Edward Michna
Evan Tzanis
Haiying Zhang
Seth Schulman
Shrividya Iyer
P304
P356
10.1016/J.JPAIN.2010.11.008
P577
2011-03-22T00:00:00Z